Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,616,553
  • Shares Outstanding, K 58,592
  • Annual Sales, $ 54,030 K
  • Annual Income, $ -412,780 K
  • EBIT $ -472 M
  • EBITDA $ -474 M
  • 60-Month Beta 0.89
  • Price/Sales 30.44
  • Price/Cash Flow N/A
  • Price/Book 1.37

Options Overview Details

View History
  • Implied Volatility 54.41% (-4.91%)
  • Historical Volatility 30.50%
  • IV Percentile 21%
  • IV Rank 7.33%
  • IV High 254.54% on 11/18/25
  • IV Low 38.58% on 05/21/25
  • Expected Move (DTE 7) 4.12 (14.80%)
  • Put/Call Vol Ratio 0.55
  • Today's Volume 17
  • Volume Avg (30-Day) 152
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 44,042
  • Open Int (30-Day) 46,906
  • Expected Range 23.73 to 31.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.82
  • Number of Estimates 6
  • High Estimate -1.76
  • Low Estimate -1.87
  • Prior Year -1.55
  • Growth Rate Est. (year over year) -17.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.83 +3.78%
on 03/06/26
31.02 -10.22%
on 02/24/26
-0.11 (-0.39%)
since 02/13/26
3-Month
24.16 +15.27%
on 12/22/25
31.02 -10.22%
on 02/24/26
+0.58 (+2.13%)
since 12/12/25
52-Week
22.24 +25.22%
on 11/19/25
46.00 -39.46%
on 11/18/25
-3.22 (-10.36%)
since 03/13/25

Most Recent Stories

More News
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK , March 11, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...

AGIO : 27.85 (+0.94%)
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO

NEW YORK , March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:

AGIO : 27.85 (+0.94%)
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO

NEW YORK , March 4, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...

AGIO : 27.85 (+0.94%)
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO

NEW YORK , March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:

AGIO : 27.85 (+0.94%)
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia  NewBridge Pharmaceuticals, a regional specialty company,...

AGIO : 27.85 (+0.94%)
Agios Pharmaceuticals: Q4 Earnings Snapshot

Agios Pharmaceuticals: Q4 Earnings Snapshot

AGIO : 27.85 (+0.94%)
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PYRUKYND ® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval...

AGIO : 27.85 (+0.94%)
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.85 (+0.94%)
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter...

AGIO : 27.85 (+0.94%)
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.85 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 29.20
2nd Resistance Point 28.70
1st Resistance Point 28.27
Last Price 27.85
1st Support Level 27.34
2nd Support Level 26.84
3rd Support Level 26.41

See More

52-Week High 46.00
Fibonacci 61.8% 36.92
Fibonacci 50% 34.12
Fibonacci 38.2% 31.32
Last Price 27.85
52-Week Low 22.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar